



AMERICAN JOURNAL OF PHARMTECH RESEARCH

Journal home page: <http://www.ajptr.com/>

Statistical Optimization of Nifedipine Transdermal Patch by D-Optimal Mixture Design

V.N.Jayesh^{1,2*}, R.D.Gupta³, U.V.S Teotia¹

1. Shri Venkateshwara University, Gajraula, J.P. Nagar, Uttar Pradesh, India

2. Grace College of Pharmacy, Kodunthirapully, Palakkad, Kerala, India

3. H.R. Institute of Pharmacy, Ghaziabad, Uttar Pradesh, India

ABSTRACT

In the present research work nifedipine transdermal patch were prepared and optimized by using D-optimal mixture design. The prepared transdermal patches were evaluated for various parameters like drug excipients compatibility study, physicochemical evaluation, mechanical properties, *In vitro* drug release and *In vitro* permeation study. The result of evaluation parameters demonstrated a successful development of transdermal patch with poly vinyl pyrrolidone (PVP) and ethyl cellulose (EC) as rate controlling polymer.

Keywords: Transdermal, D-Optimal, Permeation

*Corresponding Author Email: mltjysh2013@rediffmail.com

Received 17 January 2014, Accepted 20 January 2014

INTRODUCTION

Transdermal drug delivery system (TDDS) has been an increased interest in the drug administration via the skin for local action and systemic effects¹. For transdermal products the goal of dosage design is to maximize the flux through the skin into the systemic circulation and simultaneously minimize the retention and metabolism of the drug in the skin². Transdermal delivery of drug has gained more interest in recent years due to its advantages over oral route including passes hepatic first pass metabolism, thus achieving high systemic bioavailability of drugs, which undergo either considerable or extensive first pass metabolism and capable of sustaining the drug release for prolonged period of time. Moreover, it provides suitability for self administration and rapid termination of drug effect if needed, leading to better patient acceptance and compliance^{3,4}.

Nifedipine is calcium channel blocker, used in vasoplastic angina, chronic stable angina, hypertension, congestive heart failure and acute myocardial infarction. The drug is reported good absorption from gastrointestinal tract but its bioavailability is low (45-56 %) due to first pass metabolism and frequent dosing is required due to short biological half life⁵. Nifedipine transdermal patch may be beneficial to the patient since it reduce adverse effects and avoid the hepatic first-pass metabolism. The need for transdermal patch of nifedipine is further justified due to the requirement of maintaining unfluctuating plasma concentrations for effective management of cardiovascular risk for long period in patients⁶.

The purpose of present study was to develop transdermal patch of nifedipine to improve bioavailability and patient compliance by using PVP and EC polymer matrix.

MATERIALS AND METHOD

Materials

Ethyl cellulose, SD fine chemicals (Mumbai, India), Polyvinyl pyrrolidone, Loba chemicals (Mumbai, India), Glycerine, SD fine chemicals (Mumbai, India), Ethanol, Titan Biotech limited (Rajasthan, India), Potassium dihydrogen orthophosphate, SD fine chemicals (Mumbai, India) and Sodium hydroxide pellets, E Merck India Ltd. (Mumbai, India) were purchased from local supplier and used as such without any purification. Nifedipine was kindly gifted by Alkem (Baddi, India).

Preparation of transdermal patches

The matrix type nifedipine transdermal patches were prepared by solvent casting techniques. The casting solutions were prepared by dissolving polymers in ethanol under constant stirring for one

hour. Nifedipine and glycerine (20 % W/W of polymer blend) were then added to the polymers solution. This solution was allowed to stir until we get clear solution and stand overnight to remove all the entrapped air bubbles. The solutions were then casted onto a aluminium cups and dried in the room temperature and covered each aluminium cups with an inverted funnel for controlled evaporation of solvent⁴.

Optimization of Variables Using D-optimal mixture design

A D optimal mixture design (DESIGN EXPERT 8.0.1 demo version software) was used for the optimization of matrix type transdermal patch of nifedipine. In a mixture design, the independent factors are the components of a mixture and the response depends on the relative proportions of each factor (B.Rama & A.Shantha, 2012). It involves changing mixture composition and exploring how such changes will affect the properties of the mixture. In present study poly vinyl pyrrolidone (A) & ethyl cellulose (B) content were selected as the independent variables whereas amount of drug release (Q12), cumulative amount of drug permeated at 24h (P24), permeation flux (J). In a mixture design, the level of single mixture component cannot be changed independently & the sum of the mixture components has to be constant. The study design including independent factor, constrains of design & observed responses shown in Table 1.

Drug-excipients compatibility study

The nifedipine and mixture of nifedipine with excipients was thoroughly blended with IR grade KBR in the ratio 1:100. The blend was then made into thin pellets on a sample plate using a hand operated compression lever. The samples were then analyzed in a Perkin Elmer Model 1330 double beam IR spectrometer using KBr film as negative control (blank).

PHYSICOCHEMICAL EVALUATION OF PATCHES

Folding endurance

The folding endurance was measured manually as the reported method(7). Briefly, a strip of the film was cut evenly and repeatedly folded at the same place till it broke. The number of times the film could be folded at the same place without breaking/cracking gave the value of folding endurance.

Thickness

Thickness of prepared patches was assessed using digital micrometer (Mitutoyo, Japan) at three different places and the average value was calculated.

Uniformity of dosage unit

Uniformity of dosage unit of patches was determined by assay of 20 units individually using UV spectrophotometric method and calculate acceptance value by using soft catalyst software (Aura

pharmaceuticals, India). The acceptance value (AV) of the preparation is less than 15%, according to the JP15. In USP30, the contents should be within a range between 85% and 115%, and the relative standard deviation should be less than or equal to 6.0% (8).

Flatness

Longitudinal strips of prepared patches were cut and length of each strip was measured.

Constriction(%) was calculated using following formula

$$\text{Constriction\%} = \frac{(l_1 - l_2)}{l_2} \times 100$$

Where: l_1 was initial length of each strip and l_2 was final length.

The value $100 - \text{constriction}(\%)$ was considered as flatness of patch.

Moisture content

The prepared patches were weighed individually and kept in a desiccator containing fused calcium chloride at 40°C in an oven for 24 h. The patches were reweighed after 24 hr. The moisture content of patches were calculated using following formula(7)

$$\text{Moisture content \%} = \frac{(W_1 - W_2)}{W_2} \times 100$$

Where: W_1 was initial weight of patch and W_2 was final weight.

Moisture uptake

The dried patches, keeping over activated silica in a desiccator and then got out from desiccator and placed in a desiccator containing saturated solution of potassium chloride (84 % relative humidity) at 30°C until two successive weights found constant. Moisture uptake of patches were calculated using follow formula(7)

$$\text{Moisture uptake \%} = \frac{(W_2 - W_1)}{W_1} \times 100$$

Where: W_1 was initial weight of patch and W_2 was final weight.

Mechanical properties

The mechanical properties of transdermal patches were determined by ASTM International Test Method for Thin Plastic Sheeting (D 882-02), with an TA.XT2 texture analyzer equipment equipped with a 5 kg load cell (Stable Micro Systems, Haslemere, Surrey, UK). The patch was cut in to 50×10 mm strip and fixed between tensile grips positioned at a distance of 30 mm. The force was gradually applied till the strip broke. The tensile strength(TS) and elongation at break (EB) were calculated using directly using the software Texture Expert V.1.15 (SMS) from the stress x strain curves, and the elastic modulus was determined as the slope of the linear initial portion of this curve^{9,10}.

***In vitro* drug release study**

The *In vitro* drug release study of patches was studied using a USP 23 type 2 paddle method (Electrolab, EDT-08Lx). The patches were fixed on the glass disk with the help of a cyanoacrylate adhesive. The disk was put at the bottom of the dissolution vessel so that drug matrix exposed to dissolution medium, phosphate buffer (pH 7.4). Samples were withdrawn at predetermined interval and replaced with fresh medium. The samples were filtered through 0.45 μm filter and appropriately diluted with phosphate buffer (pH 7.4) and assayed spectrophotometrically at 238 nm.

Drug release kinetic study

To determine the mechanism of drug release, curve fitting method was used. The goodness of fit was performed using following kinetic models ¹¹⁻¹³

Zero order Model: $Q_t = Q_0 + k_0t$, where Q_t is the amount of drug dissolved in time t , Q_0 is the initial amount of drug in the solution and K_0 is the zero order release constant.

First order Model: $\ln(Q_\infty - Q_t) = \ln Q_0 + kt$, where Q_t is the amount of drug dissolved in time t , Q_0 is the initial amount of drug in the solution, Q_∞ is the amount release in time ∞ (100 % drug release) and K is the first order release constant.

Higuchi Model: $Q_t = Q_0 + K_H t^{1/2}$, where Q_t is the amount of drug dissolved in time t , Q_0 is the initial amount of drug in the solution and K_H is the Higuchi dissolution rate constant.

Korsmeyer–Peppas Model (power law): $\frac{Q_t}{Q_\infty} = k_k t^n$, or $\log Q_t = \log k_k + n \log t$ where Q_t is the amount of drug dissolved in time t , Q_∞ is the amount release in time ∞ , k_k is the rate constant and n is the diffusional exponent, this indicates the drug release mechanism.

***In vitro* skin permeation study**

The skin permeation study were performed in a modified K-C diffusion cell (cell capacity of 50 ml, cross sectional area was 3.14 cm^2). The drug permeation study was performed using pig skin obtained from local slaughter house ^{14, 15}. The skin was store at 4 to 5⁰C in saline solution until usage. The dermatome skin (thickness 140 μm) was washed with soap solution, followed by washing with distilled water.

The isolated pig skin was mounted between the donor and receptor compartment of the diffusion cell. The dermal side of skin was facing receptor compartment and patch was affixed on the skin so that drug matrix was toward skin.

The receptor compartment of the diffusion cell was filled with phosphate buffer pH 7.4. The temperature of diffusion medium was maintained at $37 \pm 0.5^\circ\text{C}$ by circulating water jacket. This

whole assembly was kept on a magnetic stirrer and solution in the receiver compartment was constantly and continuously stirred during the whole experiment using magnetic bead. The samples were withdrawn (2 ml, each time) at different time interval and phosphate buffer pH 7.4 was replaced each time. Absorbance of the sample was read spectrophotometrically at 238 nm taking phosphate buffer pH 7.4 solution, as a blank. The amount of drug permeated per square centimetre at each time interval was calculated and plotted against time.

RESULTS AND DISCUSSION

In the present study, transdermal patches of nifedipine were prepared with different polymer combinations of EC and PVP with solvent casting method. A total of 9 formulations were prepared in triplicate using a D optimal mixture design.

A FT-IR spectrum (40 scan and resolution of 1 cm^{-1}) of drug was compared with physical mixture (drug with excipients) spectrum. FTIR spectra of drug showed characteristics peaks of the N-H stretching vibration at 3431 cm^{-1} and a band with main peak at 1679 cm^{-1} indicative of the C=O stretch of the esteric group. In FT-IR spectra of physical mixture these characteristic peaks were clearly distinguished. This suggested no chemical interaction between drug and the excipients.




Figure 1. FT-IR spectra of Nifedipine (A), physical mixture of drug with excipients(B).

Table 1 D-optimal mixture design layout

Formulation	Mixture Factor		P24 ($\mu\text{g}/\text{cm}^2$)	J ($\mu\text{g}/\text{cm}^2\cdot\text{hr}$)	Q12 (%)
	A(PVP %)	B(EC%)			
F1	0.00	100.00	1599.62	68.26	24.912
F2	50.00	50.00	1712.95	73.73	60.869
F3	25.00	75.00	1636.2	70.13	47.98
F4	100.00	0.00	1862.5	78.44	78.16
F5	75.00	25.00	1794.2	76.59	63.234

Constraints

$$0\% \leq A \leq 100\%$$

$$0\% \leq B \leq 100\%$$

$$X_1 + X_2 = 100\%$$

The physicochemical evaluation data of patches was presented in table 2. The prepared patches were flexible, flat, uniform in thickness, mass and drug content. Folding endurance result showed no visible cracks. The thickness of the transdermal patches ranged between 0.31 ± 0.05 mm to 0.44 ± 0.06 mm. The transdermal patches showed good drug content which varied between 94.23 ± 0.64 and $97.52 \pm 0.76\%$, with acceptance value (AV) ranged from 2.56-5.9, within the limit (For L1, $AV \leq 15$) as per JP 15. Moreover relative standard deviation (RSD) varied from 0.50-0.78. Thus the transdermal patches complies the USP 32 content uniformity specification. The flatness study showed no constriction in the transdermal patches.

The moisture content and moisture uptake (%) behaviour of transdermal patches is illustrated in figure 2 and table 2. Moisture content and moisture uptake of transdermal patches were found to be low and as the ratio of hydrophilic polymer (HPMC) increases, both parameter (moisture content & moisture uptake) increases. Low moisture content ranged from $1.36 \pm 0.28 - 6.50 \pm 1.04\%$ helpful to maintain stability and prevent from being dried and brittle patch. The low moisture uptake ($2.52 \pm 0.36 - 4.13 \pm 0.82\%$) prevents the patches from microbial growth and bulkiness.

Table 2: Physicochemical evaluation of patches

Formulation	Thickness mm \pm SD	Flatness%	Moisture content% Mean \pm SD	Moisture uptake% Mean \pm SD	Uniformity		
					Drug Content Mean \pm SD	RSD	AV
F 1	0.32 ± 0.02	100	1.36 ± 0.28	2.52 ± 0.36	94.23 ± 0.64	0.68	5.9
F 2	0.42 ± 0.04	100	3.96 ± 0.96	3.48 ± 0.26	97.28 ± 0.56	0.58	2.56
F3	0.31 ± 0.05	100	1.98 ± 0.57	2.94 ± 0.31	95.84 ± 0.48	0.50	3.81
F 4	0.44 ± 0.06	100	6.50 ± 1.04	4.13 ± 0.82	97.52 ± 0.76	0.78	2.80
F 5	0.39 ± 0.08	100	4.03 ± 0.82	3.95 ± 0.92	96.84 ± 0.48	0.50	5.62

SD=Standard deviation, RSD= Relative standard deviation and AV= Acceptance value




Figure.2 Moisture content (%) and uptake of various formulations

The result of mechanical property study is presented in table 3. Result showed as PVP content increases TS and strain increases, EB decreases but unpredictable pattern showed by EM.

Table 3 Mechanical properties of film

Formulation	Tensile Strength(kg/cm ²)	Elastic modulus(kg/cm ²)	Elongation at break	Strain
F1	2.22±0.34	4.826±0.36	11.62±0.43	0.46±0.09
F2	1.90±0.32	4.52±0.32	12.36±1.12	0.42±0.02
F3	1.78±0.31	4.944±0.32	16.39±0.46	0.36±0.13
F4	1.76±0.41	4.512±0.26	14.53±1.30	0.39±0.03
F5	2.04±0.36	4.744±0.38	11.96±0.68	0.42±0.02




Figure 3 In vitro drug release profile of various formulations

In vitro release of nifedipine from various formulations is shown in Figure. 3. All the tested formulations exhibited a sustained release performance, in controlled manner within 12 hr. Formulation F4 showed the maximum release of 79.45 % at the end of 12 hr. Formulation F1 showed slower drug release, and showed maximum drug release of 24.91 % after 12 hr. The

release data of the tested patches were analyzed on the basis of best fit models. The correlation coefficient was calculated for different kinetic models and the model, where the correlation coefficient was close to unity, was selected as the best fit model. The correlation coefficients of different models are shown in table 4. Formulations (F1,F2,F3 andF4) gave best fit to the Higuchi kinetic model and F5 gave best fit to first order model.

Table 4 Regression coefficient value of different kinetic models

Formulation	Zero order	Higuchi Model	First order	K-Peppas
F1	0.9362	0.9563	0.9484	0.9161
F2	0.9160	0.9866	0.9682	0.9175
F3	0.8410	0.9593	0.9073	0.9509
F4	0.7400	0.9336	0.9003	0.8399
F5	0.9550	0.9608	0.9836	0.9048

In vitro skin permeation profile of various transdermal patches is shown in figure 4. The drug permeation was good and showed the similar profile as that of the drug release. F4 showed a maximum drug permeation ($1599.62 \mu\text{g}/\text{cm}^2$) over a period of 24 hr followed by F5 ($1794.2 \mu\text{g}/\text{cm}^2$), F2 ($1712.95 \mu\text{g}/\text{cm}^2$), F3 ($1636.2 \mu\text{g}/\text{cm}^2$) and F1 ($1599.62 \mu\text{g}/\text{cm}^2$). The flux (J) was found maximum with $78.44\text{mcg}/\text{cm}^2.\text{hr}$ for F4.




Figure 4 *In vitro* skin permeation of different formulation

D optimal mixture design was used for the optimization of formulation in the present work. Total 5 trial formulation of nifedipine were proposed by the D-optimal mixture design, for two mixture components: amount of HPMC (X1, %) and EC (X2,%). The effect of these variables on drug permeated per cm^2 at 24 hr (P24), permeation flux (J) and cumulative amount of drug release at 12 hr (Q12) were investigated as optimization response parameters in the current study. According to the D-optimal mixture design, 5 trial formulation of nifedipine transdermal patches were prepared by solvent casting method. Overview of the experimental trial and observed responses is presented in table.1.

The effect of mixture component on dependent variables were modelled using the following equation

$$Y_i = b_0 + b_1X_1 + b_2X_2 + b_{12}X_1X_2 + b_{11}X_1^2 + b_{22}X_2^2$$

Where Y is predicated response, b_0 is the arithmetic mean of all responses, b_1 & b_2 are the estimated coefficient for factors A & B respectively. Positive sign of the term indicates additive effect, while negative sign indicates antagonistic effect. The mathematical design for the dependent responses are as follow:

$$P24 = +1858.04 A + 1584.15 B$$

$$J = +78.83A + 67.83B$$

$$Q12 = +79.44A + 30.63B$$

The effect of mixture component on the dependent responses are shown in figure 5-7.




Figure 5 Two component mix plot for response amount permeated per cm^2 at 24 hr (P24)




Figure 6 Two component mix plot for response skin flux (J)

Design-Expert® Software

Q12
 ◆ DesignPoints
 X1 = A: PVP
 X2 = B: EC




Figure 7 Two component mix plot for response cumulative drug release at 12 hr (Q12)

A numerical optimization technique based on the desirability approaches was used to select optimized formulation with desired responses, which was also used as a check point.

Design-Expert® Software

Desirability
 ◆ DesignPoints
 X1 = A: PVP
 X2 = B: EC




Figure 8 Numerical optimization of transdermal patch on the basis of desirability

The variables setting used for the preparation of optimized transdermal patch were amount of PVP (A) and EC (B) was 90.91 % and 9.09 % respectively (Figure 8). The optimized formulations were formulated with the optimized amount of independent variable by solvent casting method. Comparison between observed and predicted value indicated that observed value of optimized transdermal patch was similar to predictive value.

CONCLUSION

In conclusion, the preparation of nifedipine transdermal patches using solvent casting method is feasible. Moreover we may prepare nifedipine transdermal patches with highest permeation rate by employing design of experiment based on D optimal mixture design. The optimized transdermal patch was prepared with 90.91 % PVP and 9.09 % EC. This developed optimized transdermal patch showed prolonged sustained release of nifedipine with high permeation rate, thus the transdermal patch of nifedipine as one of the promising tool for delivery of nifedipine in order to achieve improved patient compliance and bioavailability.

REFERENCES

1. Shailesh T. Prajapati, Charmi G. Patel, Patel CN. Formulation and Evaluation of Transdermal Patch of Repaglinide. *ISRN Pharmaceutics*. 2011;1-9.
2. Mishra AN. Transdermal Drug Delivery In: N.K.Jain, editor. *Controlled and Novel Drug Delivery*. New Delhi, India: CBS Publisher and Distributor 1997.
3. Tiwary AK, Sapra B, Jain S. Innovations in Transdermal Drug Delivery: Formulations and Techniques. *Recent Patents on Drug Delivery & Formulation*. 2007;1:23-36.
4. Ahmed MG, Kumar K, Kumar S. Formulation and Evaluation of Nifedipine Transdermal Patches. *J Pharm Res* 2010;3(8):1785-7.
5. Y. Lalitha, Lakshmi PK. Enhancement of dissolution of nifedipine by surface solid dispersion technique. *Int J Pharm Pharma Sci* 2011;3(3):41-6.
6. Benson HAE. Transdermal Drug Delivery: Penetration Enhancement Techniques. *Current Drug Delivery*. 2005;2:23-33.
7. Mamatha T., Venkateswara Rao J., Mukkanti K., G. R. Development of matrix type transdermal patches of lercanidipine hydrochloride: physicochemical and in-vitro characterization. *DARU* 2010;18(1):9-16.
8. USP. Uniformity of dosage unit. 2007.
9. Chatterjee A, Bhowmik BB, Awasthi D. Prolong Release Bioadhesive Vaginal Film of Anti-Hiv Drug (Zidovudine): Formulation and In- Vitro Evaluation. *Int J Pharma Sci Res*. 2010;1(3).
10. Peh KK, Wong CF. Polymeric Films as Vehicle for Buccal Delivery: Swelling, Mechanical, and Bioadhesive Properties. *J Pharm Pharma Sci*. 1999;2(2):53-61.
11. Awasthi R, Kulkarni GT. Development of novel gastroretentive drug delivery system of gliclazide: hollow beads. *Drug Dev Ind Pharm*. 2013;Early Online:1-11.

12. Awasthi R, Kulkarni GT. Development of Novel Gastroretentive Floating Particulate Drug Delivery System of Gliclazide. *Current Drug Delivery*. 2012;9:437-51.
13. Dash S, Murthy PN, Nath L, Chowdhury P. Kinetic modeling on drug release from controlled drug delivery systems. *Acta Poloniae Pharmaceutica - Drug Research*. 2010;67(3):217-23.
14. Barbero AM, Frasch HF. Pig and guinea pig skin as surrogates for human in vitro penetration studies: A quantitative review. *Toxicology in Vitro*. 2009;23(1):1-13.
15. Bartek MJ, Labudde JA, Maibach HI. Skin permeability in vivo: comparison in rat, rabbit, pig and man. *J Investigative Dermatology*. 1972;58:114-23.

AJPTR is

- Peer-reviewed
- bimonthly
- Rapid publication

Submit your manuscript at: editor@ajptr.com

